| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Chelsea Sierra Voss | Director | $1,246,760 | 16 Jan 2026 | ||
| Paul Rivard | Chief Legal Officer | $444,000 | 24 Aug 2023 | ||
| Joshua N. Silverman | Executive Chairman, Director | $435,126 | 14 Nov 2025 | ||
| Bruce Bernstein | Director | $108,750 | 14 Nov 2025 | ||
| Stephen Friscia | Director | $108,750 | 14 Nov 2025 | ||
| Billy Joe White | Director | $84,581 | 14 Nov 2025 | ||
| Gary M. Rauch | Vice President of Finance | $54,375 | 14 Nov 2025 | ||
| Mitchell Glass | Director, Chief Medical Off., Director | $42,250 | 14 Nov 2025 | ||
| Craig Eagle | Director | 07 Jun 2023 | |||
| Adam Kaplin | Chief Scientific Officer | 07 Jun 2023 | |||
| Christopher Chapman MD | President, Chief Med. Officer, Director | 07 Jun 2023 | |||
| Jude Uzonwanne | Director | 07 Jun 2023 | |||
| Christopher C. Schreiber | Director | 07 Jun 2023 | |||
| PharmaCyte Biotech, Inc. | 10%+ Owner | 04 Sep 2025 | |||
| Ian Rhodes | Interim CFO | 17 Apr 2025 |
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Chelsea Sierra Voss | QCLS | Common stock | Award | 9895.8% | 237,500 | 239,900 | 16 Jan 2026 | Direct | ||
| Chelsea Sierra Voss | QCLS | Employee Stock Option (Right to Buy) | Award | 212,500 | 212,500 | 16 Jan 2026 | Direct | |||
| PharmaCyte Biotech, Inc. | TNFA | Warrants | Purchase | 889,865 | 889,865 | 14 Nov 2025 | Direct | |||
| Mitchell Glass | TNFA | Common stock | Award | 1057.4% | 11,420 | 12,500 | 14 Nov 2025 | Direct | ||
| Billy Joe White | TNFA | Common stock | Award | 1045.3% | 22,839 | 25,024 | 14 Nov 2025 | Direct | ||
| Joshua Silverman | TNFA | Common stock | Award | 1053.3% | 91,356 | 100,029 | 14 Nov 2025 | Direct | ||
| Stephen Friscia | TNFA | Common stock | Award | 1056.9% | 22,839 | 25,000 | 14 Nov 2025 | Direct | ||
| Bruce Bernstein | TNFA | Common stock | Award | 25,000 | 25,000 | 14 Nov 2025 | Direct | |||
| Gary M. Rauch | TNFA | Common stock | Award | 1057.4% | 11,420 | 12,500 | 14 Nov 2025 | Direct | ||
| Joshua Silverman | TNFA | Common stock | Award | 29806.9% | 8,644 | 8,673 | 03 Oct 2025 | Direct | ||
| Stephen Friscia | TNFA | Common stock | Award | 2,161 | 2,161 | 03 Oct 2025 | Direct | |||
| Mitchell Glass | TNFA | Common stock | Award | 1,080 | 1,080 | 03 Oct 2025 | Direct | |||
| Billy Joe White | TNFA | Common stock | Award | 9004.2% | 2,161 | 2,185 | 03 Oct 2025 | Direct | ||
| Gary M. Rauch | TNFA | Common stock | Award | 1,080 | 1,080 | 03 Oct 2025 | Direct | |||
| PharmaCyte Biotech, Inc. | TNFA | Series H Convertible Preferred Stock | Purchase | 889,865 | 889,865 | 04 Sep 2025 | Direct | |||
| Gary M. Rauch | TNFA | Employee Stock Option (Right to Buy) | Award | 75,000 | 75,000 | 17 Apr 2025 | Direct | |||
| Ian Rhodes | TNFA | Employee Stock Option (Right to Buy) | Award | 25,000 | 25,000 | 17 Apr 2025 | Direct | |||
| Mitchell Glass | TNFA | Employee Stock Option (Right to Buy) | Award | 125,000 | 125,000 | 17 Apr 2025 | Direct |